Literature DB >> 31727329

Is current age related macular degeneration self-monitoring a good tool for detecting exudative recurrence?

C Chamard1, S Lacombe2, S Navarre2, C Rohart2, J-P Daures2, S Allieu2.   

Abstract

PURPOSE: To assess the ability of patients with exudative AMD to detect exudative recurrence. Another objective was to assess if self-monitoring, as currently taught, improves this ability.
MATERIALS AND METHODS: An observational cross-sectional study was carried out in the ophthalmology center of BeauSoleil clinic in Montpellier between March 1 and April 1 2016. Inclusion criteria were presence of neovascular age related macular degeneration treated with the loading dose of three monthly intravitreal anti-VEGF injections, with at least one injection in the past 12 months and at least one exudative recurrence. All patients underwent a visual acuity measurement with ETDRS charts at 4 meters. A questionnaire assessed familiarity with the Amsler grid and its proper use, performance of and type of self-monitoring at home and the subjective feeling of an exudative recurrence at the visit with a 5-level Likert scale.
RESULTS: A total of 94 eyes of 70 patients were included in this study with 69.0 % women and a median (interquartile range) age of 83 (77-96) years. Among them, 81 % performed regular self-monitoring, mostly with environmental Amsler tests (70 %). Only 63 % of the patients knew of the Amsler grid, among which 52 % used it correctly. Sensitivity (95 % confidence interval, 95 % CI) and specificity (95 % CI) of the subjective sensation of exudative recurrence were 0.32 (0.14-0.55) and 0.85 (0.74-0.92), respectively, for the entire population. Sensitivity (95 % CI) and specificity (95 % CI) were 0.33 (0.13-0.59) and 0.85 (0.74-0.93); 0.25 (0.0063-0.81) and 0.82 (0.48-0.98), respectively, in patients performing and not performing self-monitoring.
CONCLUSION: Patients' prediction in wet AMD is insufficient in detecting exudative recurrences, even if regular self-monitoring with Amsler grid or environmental Amsler is performed.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Age related macular degeneration; Amsler grid; Anti-VEGF; Autosurveillance; Dégénérescence maculaire liée à l’âge; Grille d’Amsler; Self-monitoring; VEGF inhibitors

Mesh:

Year:  2019        PMID: 31727329     DOI: 10.1016/j.jfo.2019.02.017

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  4 in total

1.  Self-Examination Low-Cost Full-Field Optical Coherence Tomography (SELFF-OCT) for neovascular age-related macular degeneration: a cross-sectional diagnostic accuracy study.

Authors:  Claus von der Burchard; Helge Sudkamp; Jan Tode; Cristoph Ehlken; Konstantine Purtskhvanidze; Moritz Moltmann; Britta Heimes; Peter Koch; Michael Münst; Malte Vom Endt; Timo Kepp; Dirk Theisen-Kunde; Inke König; Gereon Hüttmann; Johann Roider
Journal:  BMJ Open       Date:  2022-06-27       Impact factor: 3.006

2.  Self-examination low-cost full-field OCT (SELFF-OCT) for patients with various macular diseases.

Authors:  Claus von der Burchard; Moritz Moltmann; Jan Tode; Christoph Ehlken; Helge Sudkamp; Dirk Theisen-Kunde; Inke König; Gereon Hüttmann; Johann Roider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-12-21       Impact factor: 3.117

3.  Real-Life Value of the Odysight® Application in At-Home Screening for Exudative Recurrence of Macular Edema.

Authors:  Gauthier Kielwasser; Laurent Kodjikian; Corinne Dot; Carole Burillon; Philippe Denis; Thibaud Mathis
Journal:  J Clin Med       Date:  2022-08-26       Impact factor: 4.964

4.  Real-World Performance of a Self-Operated Home Monitoring System for Early Detection of Neovascular Age-Related Macular Degeneration.

Authors:  Allen C Ho; Jeffrey S Heier; Nancy M Holekamp; Richard A Garfinkel; Byron Ladd; Carl C Awh; Rishi P Singh; George E Sanborn; Jennifer H Jacobs; Michael J Elman; Anat Loewenstein; David A Eichenbaum
Journal:  J Clin Med       Date:  2021-03-25       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.